Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

II Study of VNP40101M (Cloretazine) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML)

II Study of VNP40101M (Cloretazine) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML). Blood. 2007; 110(11):279a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.